Trails are long, laborious and sadly often prone to disappointing those hoping for success. But in the spirit of Thomas Edison and all those scientists who needed 999 disasters before the 1 success, the only thing to do is just to keep on trying, the next one and the next one, and sometimes another trial but slightly differently constructed of the very same drug. Whilst we know that trials may never help us, they could help our kids or grandkids. My motto has always been “never give up”.
I took part in a phase 2 trial for Exanatide in 2015 as well as Transeuro before that and another drug trial in 2019-20. In my view, the assessment tools are just not capable of measuring someone's PD symptoms in sufficient granularity. The distinction between motor / non-motor symptoms and the focus on motor symptoms seem outdated
It seems to me that Phase 3 trials are necessarily long, expensive and onerous -- if a drug is going to get regulatory approval then there needs to be robust data to support it. And of course not every phase 3 trial will end in success. Where we seem to be failing is in the time it is taking to get to phase 3. Surely we must be able to better coordinate and accelerate all the phase 1 and phase 2 studies? Time to redouble our efforts!
Trails are long, laborious and sadly often prone to disappointing those hoping for success. But in the spirit of Thomas Edison and all those scientists who needed 999 disasters before the 1 success, the only thing to do is just to keep on trying, the next one and the next one, and sometimes another trial but slightly differently constructed of the very same drug. Whilst we know that trials may never help us, they could help our kids or grandkids. My motto has always been “never give up”.
Sharon, this is very wise. Thank you
So very disappointing for all concerned but but as Sharon rightly says the only thing to do is to keep on trying
I took part in a phase 2 trial for Exanatide in 2015 as well as Transeuro before that and another drug trial in 2019-20. In my view, the assessment tools are just not capable of measuring someone's PD symptoms in sufficient granularity. The distinction between motor / non-motor symptoms and the focus on motor symptoms seem outdated
It seems to me that Phase 3 trials are necessarily long, expensive and onerous -- if a drug is going to get regulatory approval then there needs to be robust data to support it. And of course not every phase 3 trial will end in success. Where we seem to be failing is in the time it is taking to get to phase 3. Surely we must be able to better coordinate and accelerate all the phase 1 and phase 2 studies? Time to redouble our efforts!